Nanette H. Grana
Experienced in Acute Monoblastic Leukemia (AmoL)

Dr. Nanette H. Grana

Pediatric Hematology Oncology
Johns Hopkins Medicine
Johns Hopkins All Children's Outpatient Care, St. Petersburg
601 5th Street South, Suite 320, Suite 320, 
Saint Petersburg, FL 
Clinical Trials:Currently Recruiting for 1 Trial

Experienced in Acute Monoblastic Leukemia (AmoL)
Johns Hopkins Medicine
Johns Hopkins All Children's Outpatient Care, St. Petersburg
601 5th Street South, Suite 320, Suite 320, 
Saint Petersburg, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Grana specializes in pediatric hematology/oncology in the Johns Hopkins All Children’s Cancer & Blood Disorders Institute. She joined the hospital medical staff in 1992. Dr. Grana earned her medical degree from the University of Puerto Rico School of Medicine. She trained in pediatrics at University Children’s Hospital in San Juan, Puerto Rico, and completed a pediatric hematology/oncology fellowship at the University of Florida.

Dr. Grana is rated as an Experienced provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). Her top areas of expertise are Acute Monoblastic Leukemia (AmoL), Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Immune Thrombocytopenic Purpura (ITP).

Her clinical research consists of co-authoring 3 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
University of Puerto Rico Medical Sciences, Pediatrics, 1983
Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in FL
Board Certifications
American Board Of Pediatrics
Fellowships
Shands at the University of Florida, Pediatric Hematology-Oncology, 1990
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

Johns Hopkins All Children's Outpatient Care, St. Petersburg
601 5th Street South, Suite 320, Suite 320, Saint Petersburg, FL 33701
Call: 727-767-4176
Other Locations
Johns Hopkins All Children's Outpatient Care, Tampa
12220 Bruce B Downs Boulevard, Tampa, FL 33612
Call: 727-767-4176

Additional Areas of Focus

Dr. Grana has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


8 Clinical Trials

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Enrollment Status: Recruiting
Publish Date: October 24, 2025
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Study Phase: Phase 3
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
Neuroblastoma Biology Studies
Neuroblastoma Biology Studies
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Other
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2024
Intervention Type: Other
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
Enrollment Status: Completed
Publish Date: April 30, 2024
Intervention Type: Drug
Study Drugs: Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate
Study Phase: Phase 2
A Phase I Trial of Dose Escalation of Metformin in Combination With Vincristine, Irinotecan, and Temozolomide in Children With Relapsed or Refractory Solid Tumors
A Phase I Trial of Dose Escalation of Metformin in Combination With Vincristine, Irinotecan, and Temozolomide in Children With Relapsed or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: January 13, 2023
Intervention Type: Drug
Study Drugs: Vincristine, Irinotecan, Temozolomide, Metformin
Study Phase: Phase 1
View 7 Less Clinical Trials

3 Total Publications

B-cell acute lymphoblastic leukemia with high mutation burden presenting in a child with constitutional mismatch repair deficiency.
B-cell acute lymphoblastic leukemia with high mutation burden presenting in a child with constitutional mismatch repair deficiency.
Journal: Blood advances
Published: April 25, 2019
View All 3 Publications
Similar Doctors
Jennifer L. Mayer
Experienced in Acute Monoblastic Leukemia (AmoL)
Dr. Jennifer L. Mayer
Pediatric Hematology Oncology
Experienced in Acute Monoblastic Leukemia (AmoL)
Dr. Jennifer L. Mayer
Pediatric Hematology Oncology

Johns Hopkins All Children's Outpatient Care, St. Petersburg

601 5th Street South, Suite 320, Suite 320, 
Saint Petersburg, FL 
 (0.7 miles away)
727-767-4176
Languages Spoken:
English
See accepted insurances

Dr. Mayer is a pediatric hematologist-oncologist in the Johns Hopkins All Children’s Cancer & Blood Disorders Institute. She specializes in the diagnosis and management of patients with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), Hodgkin lymphoma and non-Hodgkin lymphoma. She is also the medical director of the Vascular Anomalies and Birthmarks Program at the hospital. She cares for patients with benign and aggressive vascular tumors, lymphatic and venous malformations, and overgrowth syndromes. She was named the William A. Baumgartner Physician of the Year for Johns Hopkins All Children's in the 2024 Johns Hopkins Medicine Clinical Awards. She previously received the hospital’s Best Consulting Physician Award in 2017. Dr. Mayer is the author of more than 30 publications and two textbook chapters. She has presented over 22 research abstracts at national and international medical conferences. She is program director of a three-year fellowship training program in pediatric hematology-oncology on the St. Petersburg, Florida, campus. Dr. Mayer joined Johns Hopkins All Children’s in 1996. Dr. Mayer received her medical degree with honors from Dartmouth Medical School in New Hampshire. She completed her pediatric residency, hematology-oncology fellowship, and clinical research fellowship at Yale University School of Medicine in Connecticut. She is a fellow of the American Academy of Pediatrics and an active member and clinical researcher with Children’s Oncology Group, American Society of Pediatric Hematology-Oncology, and the International Society for the Study of Vascular Anomalies. Dr. Mayer is rated as an Experienced provider by MediFind in the treatment of Acute Monoblastic Leukemia (AmoL). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Evans Syndrome, Acute Monoblastic Leukemia (AmoL), and Teratoma of the Mediastinum.

VIEW MORE ACUTE MONOBLASTIC LEUKEMIA (AMOL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Grana's expertise for a condition
ConditionClose
        • Experienced
        • Acute Monoblastic Leukemia (AmoL)
          Dr. Grana is
          Experienced
          . Learn about Acute Monoblastic Leukemia (AmoL).
          See more Acute Monoblastic Leukemia (AmoL) experts
        • Embryonal Tumor with Multilayered Rosettes
          Dr. Grana is
          Experienced
          . Learn about Embryonal Tumor with Multilayered Rosettes.
          See more Embryonal Tumor with Multilayered Rosettes experts
        • Neuroblastoma
          Dr. Grana is
          Experienced
          . Learn about Neuroblastoma.
          See more Neuroblastoma experts
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile
        For Patients
        • Our Story
        • How MediFind Works
        • Conditions A-Z
        • Doctor Directory
        • Symptoms Directory
        • Procedures Directory
        • Treatment Directory
        • Drug Directory
        • Infusion Center Finder
        • FAQ
        • Contact Us
        For Providers and Practices
        • Claim Your Profile
        • Newsroom
        Business Solutions
        • Provider
        • Network Solutions
        Additional Resources
        • Consumer Health Data Privacy Policy
        • Privacy Policy
        • Terms of Use
        • Advertising Policy
        • Content Policy
        Subscribe to our newsletter

        Sign up to stay informed about MediFind and get wellness sent your way.

        Close

          By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

          Bullet PinMediFind
          Follow us on
          This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
          © 2026 All Rights Reserved

          Request an Appointment

          If you are experiencing a medical emergency, call 9-1-1.

          MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

          Patient Details

          This information is for the patient who will be seen at the appointment.

            Close

            Returning patient? Use your address on file with the provider.

            Insurance Details

            Please provide information of the primary insurance holder as the practice may require this information to schedule.

            Insurance Provider *
            Insurance ProviderClose

            Appointments Details

            Let’s get more information about your appointment.

                    0 / 1000
                    0 / 1000
                    By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.